ArticleInterdisciplinary sciences, computational life sciences2025
MultiKD-DTA: Enhancing Drug-Target Affinity Prediction Through Multiscale Feature Extraction.
Article in Interdisciplinary sciences, computational life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- PCIM-DTA: pairwise conditional interaction modeling for drug-target affinity prediction under cold-start scenarios.Bioinformatics (Oxford, England) · 2026Article
- MLDTA an Ensemble-Driven Multimodal Model with Dynamic Fusion for Drug-Target Affinity Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Multimodal pre-training models of molecular representation for drug discovery.National science review · 2026Review
- A survey on deep learning for drug-target binding prediction: models, benchmarks, evaluation, and case studies.Briefings in bioinformatics · 2025Review
- ProstaNet: A Novel Geometric Vector Perceptrons-Graph Neural Network Algorithm for Protein Stability Prediction in Single- and Multiple-Point Mutations with Experimental Validation.Research (Washington, D.C.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The discovery and development of novel pharmaceutical agents is characterized by high costs, lengthy timelines, and significant safety concerns. Traditional drug discovery involves pharmacologists manually screening drug molecules against protein targets, focusing on binding within protein cavities. However, this manual process is slow and inherently limited. Given these constraints, the use of deep learning techniques to predict drug-target interaction (DTI) affinities is both significant and promising for future applications. This paper introduces an innovative deep learning architecture designed to enhance the prediction of DTI affinities. The model ingeniously combines graph neural networks, pre-trained large-scale protein models, and attention mechanisms to improve performance. In this framework, molecular structures are represented as graphs and processed through graph neural networks and multiscale convolutional networks to facilitate feature extraction. Simultaneously, protein sequences are encoded using pre-trained ESM-2 large models and processed with bidirectional long short-term memory networks. Subsequently, the molecular and protein embeddings derived from these processes are integrated within a fusion module to compute affinity scores. Experimental results demonstrate that our proposed model outperforms existing methods on two publicly available datasets.
Indexed as
Identifiers
40019659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.